• About
  • Team
  • funds
    • o2h human health KI EIS
    • o2h human health SEIS
    • o2h human health EIS
  • Portfolio
  • Documents
  • news
    • Press releases
    • Blog
    • Press Coverage
    • Events
  • Login
  • Contact

o2h-ventures

  • About
  • Team
  • funds
    • o2h human health KI EIS
    • o2h human health SEIS
    • o2h human health EIS
  • Portfolio
  • Documents
  • news
    • Press releases
    • Blog
    • Press Coverage
    • Events
  • Login
  • Contact

Don’t invest unless you’re prepared to lose all your money invested. This is a high risk investment. You could lose all the money you invest and are unlikely to be protected if something goes wrong. Take 2 mins to learn more

o2h ventures backed Small Pharma receives approval for world’s first DMT for depression clinical trial
Feb 22 2021

Small Pharma receives regulatory approval for clinical trial to explore DMT for depression, which it claims is the world’s first patient clinical trial of the psychedelic.

London-based Small Pharma has been given the green light by UK regulators for a trial assessing the safety, and later efficacy, of N,N-dimethyltryptamine (DMT) in depression. The company believes that DMT can offer a shorter psychedelic therapy session, given that it “delivers a psychedelic experience in 20 minutes” according to CEO Peter Rand.

Small Pharma’s Chief Medical & Scientific Officer Carol Routledge likened the high-dose psychedelic experience to “shaking up a snow globe, disrupting unhealthy patterns of thought an providing an opportunity for them to resettle differently.”

The psychedelic experience occasioned by DMT is generally accepted to be more intense than that of peer drugs like psilocybin and is different in its nature according to Routledge.

DMT is the primary active ingredient in ayahuasca, a ceremonial brew used for spiritual and religious purposes by many tribes. Routledge suggested that, despite showing efficacy in treating patients with depression, ayahuasca “contains a bit of a cocktail of active components and so has a much poorer safety profile and is a significantly longer psychedelic experience compared to DMT.”

Last week the Financial Times reported that the UK government is set to receive a seven-figure return on an investment it made in Small Pharma via Angel CoFund, a state-backed investor that owns a 5.5% share in the company. Importantly, the fund invested in the company before it delved into psychedelic research.

Read more: 

UK Regulators Approve World’s First DMT for Depression Clinical Trial

Connect with us
  • linkedin
  • twitter
  • instagram
  • facebook
  • youtube
o2h-ventures
related stories
  • o2h Ventures qualified as a finalist as Best EIS Manager – Specialist at Growth Investor Awards 2023 14 August, 2023
  • o2h Ventures selected as finalist for best seed VC in UKBAA awards 2023 14 June, 2023
  • o2h Ventures recognized as a finalist for the EISA Impact Award for 2023 8 June, 2023

Please refer to the relevant fund’s full risk warnings contained in their Information Memorandums.

Your capital is at risk. Investing in early stage businesses involves risks, including illiquidity, lack of dividends, loss of investment and dilution, and it should be done only as part of a diversified portfolio. o2h Ventures’ funds are targeted exclusively at sophisticated or high net worth investors who understand these risks and make their own investment decisions. Tax relief depends on an individual’s circumstances and may change in the future. In addition, the availability of tax relief depends on the company invested in maintaining its qualifying status. Past performance is not a reliable indicator of future performance. You should not rely on any past performance as a guarantee of future investment performance.

o2h-ventures
The o2h team are leaders in the biotech community and have been actively involved as investors, holding various board/industry positions as well as being engaged in grassroots scientific activity for over 20 years.
Useful Links
  • About Us
  • Blog
  • Documents Centre
  • Contact Us
  • Team
News
  • o2h Ventures qualified as a finalist as Best EIS Manager – Specialist at Growth Investor Awards 2023
  • o2h Ventures selected as finalist for best seed VC in UKBAA awards 2023
  • o2h Ventures recognized as a finalist for the EISA Impact Award for 2023
Connect with us
  • linkedin
  • twitter
  • instagram
  • facebook
© 2023 o2h ventures
  • Privacy Policy
  • Blog
  • Contact us
This website is a financial promotion approved by o2h Ventures Ltd for the purposes of section 21 Financial Services and Markets Act 2000 relating to the communication of invitations or inducements to engage in investment activity. o2h ventures Limited is regulated and authorised by the Financial Conduct Authority. The FCA firm reference number is 812245 and further information can be found on the Financial Services Register.

Risk Information

Due to the potential for losses, the Financial Conduct Authority (FCA) considers this investment to be high risk

What are the key risks?

1 – You could lose all the money you invest

• If the business you invest in fails, you are likely to lose 100% of the money you invest. Most start-up businesses fail.

2 – You are unlikely to be protected if something goes wrong

• Protection from the Financial Services Compensation Scheme (FSCS), in relation to claims against failed regulated firms, does not cover poor investment performance. Try the FSCS investment protection checker here. (https://www.fscs.org.uk/check/investment-protection-checker)

• Protection from the Financial Ombudsman Service (FOS) does not cover poor investment performance. If you have a complaint against an FCA-regulated firm, FOS may be able to consider it. Learn more about FOS protection here. (https://www.financial-ombudsman.org.uk/consumers)

3 – You won’t get your money back quickly

• Even if the business you invest in is successful, it may take several years to get your money back. You are unlikely to be able to sell your investment early.

• The most likely way to get your money back is if the business is bought by another business or lists its shares on an exchange such as the London Stock Exchange. These events are not common.

• If you are investing in a start-up business, you should not expect to get your money back through dividends. Start-up businesses rarely pay these.

4 – Don’t put all your eggs in one basket

• Putting all your money into a single business or type of investment for example, is risky. Spreading your money across different investments makes you less dependent on any one to do well.

• A good rule of thumb is not to invest more than 10% of your money in high-risk investments (https://www.fca.org.uk/investsmart/5-questions-ask-you-invest)

5 – The value of your investment can be reduced

• The percentage of the business that you own will decrease if the business issues more shares. This could mean that the value of your investment reduces, depending on how much the business grows. Most start-up businesses issue multiple rounds of shares.

• These new shares could have addition rights that your shares don’t have, such as the right to receive a fixed dividend, which could further reduce your chances of getting a return on your investment.

If you are interested in learning more about how to protect yourself, visit the FCA’s website here (https://www.fca.org.uk/investsmart)